Anti-viral drug treatment: Dynamics of resistance in free virus and infected cell populations

被引:206
作者
Nowak, MA [1 ]
Bonhoeffer, S [1 ]
Shaw, GM [1 ]
May, RM [1 ]
机构
[1] UNIV ALABAMA, DIV HEMATOL ONCOL, BIRMINGHAM, AL 35294 USA
基金
英国惠康基金;
关键词
D O I
10.1006/jtbi.1996.0307
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Anti-viral drug treatment of infections with the human immunodeficiency virus type 1 (HIV-1) usually leads to a rapid decline in the abundance of plasma virus. The effect of single drug therapy, however, is often only short-lived as the virus readily develops drug-resistant mutants. In this paper we provide analytic approximations for the rate of emergence of resistant virus. We study the decline of wildtype virus and the rise of resistant mutant virus in different compartments of the virus population such as free plasma virus, cells infected with actively replicating virus, long-lived infected cells and cells carrying defective provirus. The model results are compared with data on the rise of drug-resistant virus in three HIV-1 infected patients treated with neverapine (NVP). We find that the half-life of latently infected cells is between 10 and 20 days, whereas the half-life of cells with defective provirus is about 80 days. We also provide a crude estimate for the basic reproductive ratio of HIV-1 during NVP therapy. (C) 1997 Academic Press Limited.
引用
收藏
页码:205 / 219
页数:15
相关论文
共 45 条
[1]  
ANDERSON R M, 1991
[2]   ZIDOVUDINE SENSITIVITY OF HUMAN IMMUNODEFICIENCY VIRUSES FROM HIGH-RISK, SYMPTOM-FREE INDIVIDUALS DURING THERAPY [J].
BOUCHER, CAB ;
TERSMETTE, M ;
LANGE, JMA ;
KELLAM, P ;
DEGOEDE, REY ;
MULDER, JW ;
DARBY, G ;
GOUDSMIT, J ;
LARDER, BA .
LANCET, 1990, 336 (8715) :585-590
[3]   ORDERED APPEARANCE OF ZIDOVUDINE RESISTANCE MUTATIONS DURING TREATMENT OF 18 HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS [J].
BOUCHER, CAB ;
OSULLIVAN, E ;
MULDER, JW ;
RAMAUTARSING, C ;
KELLAM, P ;
DARBY, G ;
LANGE, JMA ;
GOUDSMIT, J ;
LARDER, BA .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) :105-110
[4]   HIV-1 BIOLOGICAL PHENOTYPE AND THE DEVELOPMENT OF ZIDOVUDINE RESISTANCE IN RELATION TO DISEASE PROGRESSION IN ASYMPTOMATIC INDIVIDUALS DURING TREATMENT [J].
BOUCHER, CAB ;
LANGE, JMA ;
MIEDEMA, FF ;
WEVERLING, GJ ;
KOOT, M ;
MULDER, JW ;
GOUDSMIT, J ;
KELLAM, P ;
LARDER, BA ;
TERSMETTE, M .
AIDS, 1992, 6 (11) :1259-1264
[5]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[6]   GENOMIC STRUCTURE OF AN ATTENUATED QUASI-SPECIES OF HIV-1 FROM A BLOOD-TRANSFUSION DONOR AND RECIPIENTS [J].
DEACON, NJ ;
TSYKIN, A ;
SOLOMON, A ;
SMITH, K ;
LUDFORDMENTING, M ;
HOOKER, DJ ;
MCPHEE, DA ;
GREENWAY, AL ;
ELLETT, A ;
CHATFIELD, C ;
LAWSON, VA ;
CROWE, S ;
MAERZ, A ;
SONZA, S ;
LEARMONT, J ;
SULLIVAN, JS ;
CUNNINGHAM, A ;
DWYER, D ;
DOWTON, D ;
MILLS, J .
SCIENCE, 1995, 270 (5238) :988-991
[7]   DIVERSITY AND VIRULENCE THRESHOLDS IN AIDS [J].
DEBOER, RJ ;
BOERLIJST, MC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (02) :544-548
[8]   Anti-CD4 therapy for AIDS suggested by mathematical models [J].
DeBoer, RJ ;
Boucher, CAB .
PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 1996, 263 (1372) :899-905
[9]  
DEJONG MD, 1996, IN PRESS P NAT ACAD
[10]   TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER [J].
ERON, JJ ;
BENOIT, SL ;
JEMSEK, J ;
MACARTHUR, RD ;
SANTANA, J ;
QUINN, JB ;
KURITZKES, DR ;
FALLON, MA ;
RUBIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1662-1669